On March 15, 2023, the SMEs Service Administration of Shenzhen released the list of “Specialized and Sophisticated SMEs that Produce Novel and Unique Products” in Shenzhen for the year 2022. EurekaBio was honored with this prestigious recognition following a rigorous evaluation process led by industry experts. They meticulously evaluated EurekaBio's expertise in the field of CGT research, unwavering commitment to meticulous quality management, unique business models, and innovative core technologies. 

Announcement of the SMEs Service Administration of Shenzhen on the List of Specialized and Sophisticated SMEs that Produce Novel and Unique Products in Shenzhen

The inclusion of EurekaBio as a “Specialized and Sophisticated Enterprise that Produces Novel and Unique Products” in Shenzhen signifies an eminent validation of its unparalleled professionalism, remarkable technological innovation capabilities, influential industry presence, and comprehensive overall strength.
A Specialized and Sophisticated Enterprise that Produce Novel and Unique Products in Shenzhen refers to a company whose main business and development focus aligns with national industrial policies and related requirements. These enterprises are characterized by specialization, refinement, distinctiveness, and novelty. They demonstrate a strong capacity for innovation, rapid development, operational excellence, robust financing capabilities, and commendable economic performance. They serve as trailblazers across diverse sectors, propelling economic and societal advancement with their resolute dynamism.
Since its inception, EurekaBio has remained committed to independent research and development of core technologies and products in the field of CGT. Guided by the values of "Innovation, Rigor, and Continuous Improvement," the company is driven by a mission to “Empowering CGT and Confronting the Toughest Challenges in the Industry” to support cost reduction and efficiency improvement in China's CGT industry. It has independently developed the CellSep® fully closed and automated cell processing system,  successfully breaking the market monopoly of imported products and enabling domestic production of critical equipment for cell therapy products; in addition, it has innovatively developed the EuLV®  system (and related amplification processes) that is based on stable cell producer lines and enables the large-scale production of lentiviral vectors, overcoming the technical bottleneck of lentiviral vector scale-up production with groundbreaking, innovative technologies. 

In the future, EurekaBio will continue to serve as a prime example of a “Specialized and Sophisticated Enterprise that Produces Novel and Unique Products”. We are committed to intensifying our innovation and R&D endeavors, continuously expanding our product line, strengthening our technical service capabilities, and further advancing the industrialization and commercialization of CGT drugs. Through these efforts, EurekaBio aims to make greater contributions to the sustainable development of the CGT industry.